Michael Goettler, Viatris CEO
First interchangeable biosimilar launches in the US with a tiny discount on list price
Viatris (formerly known as Mylan and Pfizer’s Upjohn) on Tuesday opened up on the pricing of its interchangeable biosimilar for the insulin Lantus, saying the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.